Affluent Medical Lists On Euronext Paris - €25 Million Raised – Market Capitalisation Of Over €156 Million mondovisione.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondovisione.com Daily Mail and Mail on Sunday newspapers.
Largo Lists On Euronext Growth Paris - â¬22.85 Million Raised â Market Capitalisation Of â¬46.1 Million Date
23/04/2021
Euronext today congratulates Largo, an eco-responsible French player in the refurbishment of mobile devices, on its listing on Euronext Growth Paris (ticker code: ALLGO).
Created in 2016, Largo specialises in the refurbishment of smartphones, tablets and laptops, and currently has almost 40 employees based in Nantes. Positioned along the entire value chain, from sourcing to refurbishment and distribution, Largo aims to become a benchmark player in the field of responsible refurbishment.
Largo was listed through the admission to trading of the 3,453,410 shares making up its equity, of which 1,515,210 new shares and 196,145 existing shares were allocated within a Global Offering[1], including the full exercise of the extension option and excluding the potential exercise of an over-allotment option.
Pherecydes Pharma Lists On Euronext Growth Paris To Accelerate Its Fight Against Antibiotic-Resistant Bacteria Date
05/02/2021
Euronext today congratulates Pherecydes Pharma, the French biotech company specialising in the treatment of bacterial infections, especially those that are complicated and/or resistant to antibiotics, on its listing on Euronext Growth Paris (ticker code: ALPHE).
Pherecydes Pharma was created in 2006. Its headquarters are in Nantes, and its research and development centre is based in Romainville. The company develops treatments based on the use of bacteriophage viruses, or phages, to fight bacterial infections that do not respond to antibiotic treatment. According to the World Health Organisation, antibiotic resistance could be responsible for more than 10 million deaths per year by 2050[1]. The capital raised will allow Pherecydes Pharma to conduct further clinical tests and potentially to make the medicines available through temporary authorisations